Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 1

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 1
---
, par value $0.0001 (the “MIRA Common Stock”). Stockholders of record at the close of business on July 21, 2025 are entitled to notice of and are cordially invited to attend the Annual Meeting. At the MIRA Annual Meeting, unless postponed or adjourned to a later date, MIRA will ask its holders of MIRA Common Stock to, among other things:

| 1. 
 2. 
 3. 
 4. | approve                                                                                                                               
 the issuance of shares of MIRA Common Stock or other securities of MIRA pursuant to the Merger as defined below, which will represent 
 (or are convertible into) more than 20% of the shares of MIRA Common Stock outstanding immediately prior to the Merger, pursuant      
 to Nasdaq Listing Rule 5635(a) (the “Merger Proposal” or “Proposal No. 1”);                                                           
 elect                                                                                                                                 
 five directors to the board of directors of the Company (the “Board”) to serve until the next annual meeting of stockholders          
 or until their successors have been duly elected or appointed and qualified (“Director Appointment Proposal” or “Proposal             
 No. 2);                                                                                                                               
 ratify                                                                                                                                
 the appointment of Salberg & Company, P.A. as the Company’s independent registered public accounting firm for the fiscal              
 year ending December 31, 2025 (the “Auditor Appointment Proposal” or “Proposal No. 3”);                                               
 to                                                                                                                                    
 approve certain amendments to the Company’s 2022 Omnibus Incentive Plan (the “Plan”) (“Plan Amendment Proposal”                       
 or “Proposal No. 4”); and                                                                                                             |
|:---|:--------------------------------------------------------------------------------------------------------------------------------------|
| 5. | approve                                                                                                                               
 a postponement or adjournment of the MIRA Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient     
 votes in favor of Proposal No. 1, Proposal No. 2, Proposal No. 3, or Proposal No. 4, the “Adjournment Proposal” or “Proposal          
 No. 5”).                                                                                                                              |

Please refer to the attached proxy statement for further information with respect to the business to be transacted at the MIRA Annual Meeting.

MIRA and SKNY Pharmaceuticals, Inc. (“SKNY”) have entered into an Agreement and Plan of Merger and Reorganization, dated June 16, 2025 (the “Merger Agreement”), pursuant to which a wholly